



65 West Watkins Mill Road
Gaithersburg, MD 20878
tel: 240-632-0740
fax: 240-632-0735
www.genvec.com

FOR IMMEDIATE RELEASE:

CONTACT:

Douglas J. Swirsky
Chief Financial Officer
(240) 632-5510
dswirsky@genvec.com

**GENVEC TO PRESENT AT RODMAN & RENSHAW 9TH
ANNUAL HEALTHCARE CONFERENCE**

GAITHERSBURG, MD – October 30, 2007 – GenVec, Inc. (Nasdaq: GNVC) announced today that Paul H. Fischer, Ph.D., President and CEO, will be presenting at the Rodman & Renshaw 9th Annual Healthcare Conference on Tuesday, November 6 at 10:35 AM ET at The New York Palace Hotel in New York City.

A live webcast of Dr. Fischer's presentation will be available on the Company's web site at www.genvec.com and archived for 30 days. To access the webcast or the replay, go to the "Investor Relations" page, and click on the link to the Webcasts and Data section.

The Conference will include presentations by over 300 companies, as well as experts from the medical, scientific, and investment communities. The Conference will be attended by investors, venture capitalists, company executives, scientists, and other industry leaders.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade™ is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza.

Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

###